Kura Oncology

$31.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.70 (-2.19%) Today
$0.00 (0.00%) As of 6:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Kura Oncology and other stocks, options, and ETFs commission-free!

About KURA

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. Read More The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA. The listed name for KURA is Kura Oncology, Inc. Common Stock.

CEO
Troy E. Wilson
Employees
60
Headquarters
San Diego, California
Founded
2014
Market Cap
1.76B
Price-Earnings Ratio
Dividend Yield
Average Volume
544.29K
High Today
$31.91
Low Today
$30.54
Open Price
$31.76
Volume
376.73K
52 Week High
$35.25
52 Week Low
$6.35

Collections

KURA Earnings

-$0.44
-$0.29
-$0.15
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Available Nov 5, Pre-Market

You May Also Like